New Therapeutic Strategy and Innovative Lubricating Ophthalmic Solution in Minimizing Dry Eye Disease Associated with Cataract Surgery: A Randomized, Prospective Study

Aim To review published literature concerning cataract surgery and dry eye disease (DED). Methods A search was undertaken using the following: PubMed (all years), Web of Science (all years), Ovid MEDLINE(R) (1946 to 12 December 2019), Ovid MEDLINE(R) Daily Update 10 December 2019, MEDLINE and MEDLINE non-indexed items, Embase (1974–2019, week 49), Ovid MEDLINE (R) and Epub Ahead of Print, In-Process and Other Non-Indexed Citations and Daily (1946 to 12 December 2019), CENTRAL (including Cochrane Eyes and Vision Trials Register; Cochrane Library: Issue 12 of 12 December 2019), metaRegister of Controlled Trials (mRCT) ( www.controlled-trials.com ), ClinicalTrials.gov ( www.clinicaltrial.gov ) and WHO International Clinical Trials Registry Platform ( www.who.int/ictrp/search/en ). Search terms included ‘cataract surgery’, ‘phacoemulsification’ and ‘cataract extraction’, combined with ‘dry eyes’ and ‘ocular surface’. Relevant in-article references not returned in our searches were also considered. Results Publications identified included systematic reviews, meta-analysis, randomized controlled trials, cohort studies, case series and laboratory-based studies. Published data highlighting the burden of DED both prior and following cataract surgery were reviewed as well as studies highlighting the effects of cataract surgery on the ocular surface, intra-operative measures to reduce deleterious effects on the ocular surface and current evidence on the management options of post-operative DED. Conclusions DED is common and can be exacerbated by cataract surgery. Ophthalmologists need to assess for pre-existing DED and instigate treatment before surgery; be aware of reduced accuracy of measurements for surgical planning in the presence of DED; limit intra-operative surgical factors damaging to the ocular surface; and consider management to reduce DED post-operatively.

Download Full-text

Rebamipide ophthalmic solution modulates the ratio of T�helper cell 17/regulatory T cells in dry eye disease mice

Molecular Medicine Reports ◽

10.3892/mmr.2019.10068 ◽

2019 ◽

Cited By ~ 2

Author(s):

Rongrong Fu ◽

Yanhua Jiang ◽

Jing Zhou ◽

Jinsong Zhang

Keyword(s):

T Cells ◽

Regulatory T Cells ◽

Dry Eye ◽

Ophthalmic Solution ◽

Dry Eye Disease ◽

T Helper Cell ◽

Helper Cell ◽

Eye Disease ◽

T Helper

Download Full-text

OP0237 Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: combined evidence from 5 randomized controlled trials

10.1136/annrheumdis-2017-eular.5890 ◽

2017 ◽

Author(s):

C Baudouin ◽

M Darvish-Zargar ◽

EJ Holland ◽

CC Chan ◽

KK Nichols ◽

...

Keyword(s):

Randomized Controlled Trials ◽

Dry Eye ◽

Ophthalmic Solution ◽

Dry Eye Disease ◽

Eye Disease ◽

Controlled Trials ◽

Randomized Controlled

Download Full-text

Effects of Cyclosporine 0.05% ophthalmic solution on diagnostic parameters of dry eye disease

International Journal of Research in Medical Sciences ◽

10.18203/2320-6012.ijrms20174160 ◽

2017 ◽

Vol 5 (10) ◽

pp. 4289

Author(s):

Maneesha Sethi ◽

Amarjeet Singh Bali ◽

P. Sadhotra

Keyword(s):

Dry Eye ◽

Tear Film ◽

Ophthalmic Solution ◽

Dry Eye Disease ◽

Diagnostic Tools ◽

Eye Disease ◽

Inclusion Criteria ◽

Ocular Surface Disease Index ◽

Diagnostic Parameters ◽

A Prospective Study

Background: Dry eye is a multifactorial disease particularly prevalent in Asia for which there are several treatments. Among anti-inflammatory treatment, cyclosporine 0.05% is preferred therapy. Our study evaluated effects of cyclosporine 0.05% ophthalmic solution on the diagnostic tools of dry eye.Material & Methods: A prospective study was carried out in ophthalmological outpatient department of ASCOMS and Hospital. Total 60 patients of dry eye disease who fulfilled the inclusion criteria were treated with cyclosporine 0.05% ophthalmic solution twice a day. The diagnostic parameters of dry eye were assessed at baseline, at month 1 and 3. Patients underwent Ocular Surface Disease Index (OSDI) score, Schirmer’s test, Tear film break up time (TBUT) .Results: After three months, mean OSDI score was significantly improved (p < 0.001). There was significant improvement in mean Schirmer score (p < 0.001). Baseline TBUT also increased significantly (p < 0.001). Conclusion: Cyclosporine 0.05% ophthalmic solution has significant effect on diagnostic parameters of dry eye disease.

Download Full-text

Evaluation of Dry Eye Disease Post-Cataract Surgery using Symptom Questionnaire and Tear Film Tests

International Journal of Current Research and Review ◽

10.31782/ijcrr.2020.12134 ◽

2020 ◽

Vol 12 (13) ◽

pp. 19-24

Author(s):

Jasmitha B. Rajashekarreddy ◽

Pradeep T. Manchegowda ◽

Varsha G Belamgi

Keyword(s):

Cataract Surgery ◽

Dry Eye ◽

Tear Film ◽

Dry Eye Disease ◽

Eye Disease ◽

Symptom Questionnaire

Download Full-text

Improved accuracy of intraocular lens power calculation by preoperative management of dry eye disease

BMC Ophthalmology ◽

10.1186/s12886-021-02129-5 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Jinsoo Kim ◽

Mee Kum Kim ◽

Yuseung Ha ◽

Hae Jung Paik ◽

Dong Hyun Kim

Keyword(s):

Cataract Surgery ◽

Intraocular Lens ◽

Dry Eye ◽

Dry Eye Disease ◽

Eye Disease ◽

Power Calculation ◽

Power Prediction ◽

Loteprednol Etabonate ◽

Iol Power ◽

Refractive Surprise

Abstract Background To evaluate the effects of pretreatment for dry eye disease (DED) on the accuracy of intraocular lens (IOL) power calculation. Methods Patients who underwent uneventful cataract surgery were included in the study. IOL power was determined using the SRK/T and Barrett Universal II (Barrett) formulas. The patients were divided into non-pretreatment and pretreatment groups, and those in the pretreatment group were treated with topical 0.5% loteprednol etabonate and 0.05% cyclosporin A for 2 weeks prior to cataract surgery. Ocular biometry was performed in all groups within 2 days before surgery. The mean prediction error, mean absolute error (MAE), and proportions of refractive surprise were compared between the non-pretreatment and pretreatment groups at 1 month postoperatively. Refractive surprise was defined as MAE ≥ 0.75D. Results In a total of 105 patients, 52 (52 eyes) were in the non-pretreatment group and 53 (53 eyes) in the pretreatment group. The MAE was 0.42 ± 0.33, 0.38 ± 0.34 (SRK/T, Barrett) and 0.23 ± 0.19, 0.24 ± 0.19 in the non-pretreatment and pretreatment groups, respectively (p < 0.001/=0.008). The number of refractive surprises was also significantly lower in the pretreatment group. [non-pretreatment/pretreatment: 9/2 (SRK/T); 8/1 (Barrett); p = 0.024/0.016]. Pretreatment of DED was related to a reduction in postoperative refractive surprise. [SRK/T/Barrett: OR = 0.18/0.17 (95% CI: 0.05–0.71/0.05–0.60), p = 0.014/0.006]. Conclusions The accuracy of IOL power prediction can be increased by actively treating DED prior to cataract surgery.

Download Full-text